TP53 and prostate carcinoma: Thus, these results expand our understanding of the dysregulation of CXCR4 expression in prostate cancer progression, suggesting that negative regulation of CXCR4 signaling by wt-p53 might be mediated through both transcriptional and post-translational mechanisms.